Literature DB >> 2539180

The prophylactic role of intravenous and long-term oral acyclovir after allogeneic bone marrow transplantation.

P J Selby1, R L Powles, D Easton, T J Perren, K Stolle, B Jameson, A P Fiddian, Y Tryhorn, H Stern.   

Abstract

Eighty-two patients were randomly allocated to receive intravenous acyclovir 5 mg kg-1 t.d.s. for 23 days followed by oral acyclovir 800 mg 6-hourly for 6 months or matching placebos after allogeneic bone marrow transplantation. Herpes simplex and varicella zoster virus infections were significantly reduced during the period of administration of acyclovir. No reduction in cytomegalovirus infection was demonstrated. The drug was not toxic.

Entities:  

Mesh：

Substances：

Year:  1989        PMID： 2539180      PMCID： PMC2247066          DOI： 10.1038/bjc.1989.88

Source DB:  PubMed          Journal:  Br J Cancer        ISSN： 0007-0920            Impact factor:   7.640


  15 in total

Review 1.  NIH Conference. Herpes simplex virus infection: biology, treatment, and prevention.

Authors:  S E Straus; J F Rooney; J L Sever; M Seidlin; S Nusinoff-Lehrman; K Cremer
Journal:  Ann Intern Med       Date:  1985-09       Impact factor: 25.391

2.  On the use of Pocock and Simon's method for balancing treatment numbers over prognostic factors in the controlled clinical trial.

Authors:  L S Freedman; S J White
Journal:  Biometrics       Date:  1976-09       Impact factor: 2.571

3.  Possible protective role against alcoholism for aldehyde dehydrogenase isozyme deficiency in Japan.

Authors:  S Harada; D P Agarwal; H W Goedde; S Tagaki; B Ishikawa
Journal:  Lancet       Date:  1982-10-09       Impact factor: 79.321

4.  Multicenter collaborative trial of intravenous acyclovir for treatment of mucocutaneous herpes simplex virus infection in the immunocompromised host.

Authors:  J D Meyers; J C Wade; C D Mitchell; R Saral; P S Lietman; D T Durack; M J Levin; A C Segreti; H H Balfour
Journal:  Am J Med       Date:  1982-07-20       Impact factor: 4.965

5.  Oral acyclovir for prevention of herpes simplex virus reactivation after marrow transplantation.

Authors:  J C Wade; B Newton; N Flournoy; J D Meyers
Journal:  Ann Intern Med       Date:  1984-06       Impact factor: 25.391

6.  Sequential intravenous and twice-daily oral acyclovir for extended prophylaxis of herpes simplex virus infection in marrow transplant patients.

Authors:  D H Shepp; P S Dandliker; N Flournoy; J D Meyers
Journal:  Transplantation       Date:  1987-05       Impact factor: 4.939

7.  Prophylaxis of herpes infections after bone-marrow transplantation by oral acyclovir.

Authors:  E Gluckman; J Lotsberg; A Devergie; X M Zhao; R Melo; M Gomez-Morales; T Nebout; M C Mazeron; Y Perol
Journal:  Lancet       Date:  1983-09-24       Impact factor: 79.321

8.  Amino (hydroxyethoxymethyl) purine: a new well-absorbed prodrug of acyclovir.

Authors:  P Selby; R L Powles; S Blake; K Stolle; E K Mbidde; T J McElwain; E Hickmott; P D Whiteman
Journal:  Lancet       Date:  1984-12-22       Impact factor: 79.321

9.  Acyclovir prophylaxis against herpes virus infections in severely immunocompromised patients: randomised double blind trial.

Authors:  I M Hann; H G Prentice; H A Blacklock; M G Ross; D Brigden; A E Rosling; C Burke; D H Crawford; W Brumfitt; A V Hoffbrand
Journal:  Br Med J (Clin Res Ed)       Date:  1983-08-06

10.  Acyclovir prophylaxis of herpes-simplex-virus infections.

Authors:  R Saral; W H Burns; O L Laskin; G W Santos; P S Lietman
Journal:  N Engl J Med       Date:  1981-07-09       Impact factor: 91.245
View more
  16 in total

Review 1.  Prophylaxis against herpesvirus infections in transplant recipients.

Authors:  P Ljungman
Journal:  Drugs       Date:  2001       Impact factor: 9.546

Review 2.  Prevention of viral infections after bone marrow transplantation.

Authors:  U Schuler; G Ehninger
Journal:  Ann Hematol       Date:  1992-06       Impact factor: 3.673

3.  Vaccination of autologous stem cell transplant recipients with live varicella vaccine: a pilot study.

Authors:  P Ljungman; F Z Wang; C Nilsson; V Solheim; A Linde
Journal:  Support Care Cancer       Date:  2003-09-17       Impact factor: 3.603

Review 4.  Antiviral therapy: current concepts and practices.

Authors:  B Bean
Journal:  Clin Microbiol Rev       Date:  1992-04       Impact factor: 26.132

5.  Safety and reactogenicity of the recombinant zoster vaccine after allogeneic hematopoietic cell transplantation.

Authors:  Emily Baumrin; Natalie E Izaguirre; Bruce Bausk; Monica M Feeley; Camden P Bay; Qiheng Yang; Vincent T Ho; Lindsey R Baden; Nicolas C Issa
Journal:  Blood Adv       Date:  2021-03-23

6.  Zoster prophylaxis after allogeneic hematopoietic cell transplantation using acyclovir/valacyclovir followed by vaccination.

Authors:  Kareem Jamani; Judy MacDonald; Martin Lavoie; Tyler S Williamson; Christopher B Brown; Ahsan Chaudhry; Victor H Jimenez-Zepeda; Peter Duggan; Jason Tay; Douglas Stewart; Andrew Daly; Jan Storek
Journal:  Blood Adv       Date:  2016-11-30

7.  Management of herpes simplex virus type 1 pneumonia following liver transplantation.

Authors:  P Liebau; E Kuse; M Winkler; H J Schlitt; K Oldhafer; W Verhagen; J Flik; R Pichlmayr
Journal:  Infection       Date:  1996 Mar-Apr       Impact factor: 3.553

8.  Long-term acyclovir for prevention of varicella zoster virus disease after allogeneic hematopoietic cell transplantation--a randomized double-blind placebo-controlled study.

Authors:  Michael Boeckh; Hyung W Kim; Mary E D Flowers; Joel D Meyers; Raleigh A Bowden
Journal:  Blood       Date:  2005-11-10       Impact factor: 22.113

9.  Development of an IFN-γ ELISpot assay to assess varicella-zoster virus-specific cell-mediated immunity following umbilical cord blood transplantation.

Authors:  Insaf Salem Fourati; Anne-Julie Grenier; Élyse Jolette; Natacha Merindol; Philippe Ovetchkine; Hugo Soudeyns
Journal:  J Vis Exp       Date:  2014-07-09       Impact factor: 1.355

10.  Varicella zoster virus encephalomyelitis as a late complication following haematopoietic stem cell transplantation.

Authors:  Lokesh Shahani
Journal:  BMJ Case Rep       Date:  2014-12-19
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.